摘要
目的分析替罗非班联合抗血小板药物治疗短暂性脑缺血发作(TIA)的临床效果。方法92例短暂性脑缺血发作患者,随机分为观察组和对照组,每组46例。两组患者入院后均给予降压、调脂、控制血糖、皮下注射低分子肝素钙等常规治疗,在此治疗基础上,对照组患者口服抗血小板药物阿司匹林进行治疗,观察组患者给予替罗非班联合阿司匹林进行治疗。比较两组患者治疗效果、治疗前后主要治疗指标[血小板计数(PLT)、凝血酶原时间(PT)、纤维蛋白原(FIB)、活化部分凝血活酶时间(APTT)、血小板内皮细胞粘附分子-1(PECAM-1)]、不良反应发生情况。结果观察组患者治疗总有效率为91.30%,显著高于对照组的73.91%,差异具有统计学意义(P<0.05)。治疗后,两组患者PLT、PT、APTT、FIB水平组间比较差异均无统计学意义(P>0.05)。治疗后,观察组患者PECAM-1水平为(77.45±9.23)μg/L,显著高于对照组的(64.66±8.57)μg/L,差异有统计学意义(P<0.05)。观察组患者不良反应发生率为4.35%,与对照组的6.52%比较差异无统计学意义(P>0.05)。结论替罗非班联合抗血小板药物治疗短暂性脑缺血发作,可显著提高患者的临床疗效,降低其反复发作次数,且不会增加患者的不良反应,具有较高的治疗安全性。
Objective To analyze the clinical effect of tirofiban combined with antiplatelet drugs in the treatment of transient ischemic attack(TIA).Methods A total of 92 patients with transient ischemic attack were randomly divided into observation group and control group,with 46 cases in each group.After admission,patients in both groups were given conventional treatments such as antihypertensive,lipid regulation,blood glucose control,and subcutaneous injection of low-molecular heparin calcium.On the basis of this treatment,patients in the control group were treated with oral antiplatelet drug aspirin,while patients in the observation group were treated with tirofiban and aspirin.Both groups were compared in terms of therapeutic effect,main treatment indexes[platelet count(PLT),prothrombin time(PT),fibrinogen(FIB),activated partial thromboplastin time(APTT),platelet endothelial cell adhesion molecule-1(PECAM-1)]before and after treatment,and the occurrence of adverse reactions.Results The total effective rate of treatment in the observation group was 91.30%,which was significantly higher than 73.91%in the control group,and the difference was statistically significant(P<0.05).After treatment,there was no statistically significant difference in PLT,PT,APTT and FIB levels between the two groups(P>0.05).After treatment,the PECAM-1 level in the observation group was(77.45±9.23)μg/L,which was significantly higher than(64.66±8.57)μg/L in the control grou,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 4.35%,and the difference was not statistically significant compared with 6.52%in the control group(P>0.05).Conclusion The combination of tirofiban with antiplatelet drugs in the treatment of transient ischemic attack can significantly improve the clinical efficacy of patients,reduce the number of their recurrent attacks,and does not increase the adverse reactions of patients,which has a high therapeutic safety.
作者
马欢
MA Huan(Jinzhou District First People's Hospital,Dalian 116000,China)
出处
《中国实用医药》
2023年第3期93-95,共3页
China Practical Medicine
关键词
替罗非班
抗血小板药物
短暂性脑缺血
治疗效果
凝血指标
不良反应
Tirofiban
Antiplatelet drugs
Transient ischemic attack
Therapeutic effect
Coagulation index
Adverse reactions
